About Us

About Eikonizo

We aim to develop life-changing therapies

Eikonizo (ee-kƏ-NEE’-zo) verb [Greek] to envision, visualize, or imagine.

The name captures our strategy to use neuroimaging earlier in the drug discovery process to de-risk therapeutic approaches to neurodegeneration.

Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.

Urgency and empathy are what drive us

Our approach de-risks and hastens clinical development

Trusted professionals

Leaders & Directors

Janice Kranz, PhD
CEO & Co-Founder
Kevin Kinsella
Director
William Shaw, JD
Co-Founder & Director
Our Lead Program

Eikonizo is developing brain-penetrant, small molecule, selective histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative diseases, focusing first on amyotrophic lateral sclerosis (ALS).